Previous 10 | Next 10 |
Assembly Biosciences (NASDAQ:ASMB): Q2 GAAP EPS of -$0.55 beats by $0.11. Cash, cash equivalents and marketable securities of $199.1M Press Release For further details see: Assembly Biosciences EPS beats by $0.11
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second ...
Assembly Biosciences (NASDAQ:ASMB) announces the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategi...
SOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that Sir Michael Houghton, PhD, has been appointed...
Shares of Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at $3.35, breaking its 52-week low. So far today approximately 322,000 shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares. There is potential upside of 20.1% for shares of Assembly Biosc...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at a new 52-week low of $3.51. So far today approximately 322,000 shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. Potential upside of 15.0% exists for Assembly Biosciences Inc., based on a cur...
Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded at a new 52-week low today of $3.56. Approximately 322,000 shares have changed hands today, as compared to an average 30-day volume of 1.5 million shares. Assembly Biosciences Inc. has overhead space with shares priced $3.58, or 12.1% below ...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded at a new 52-week low today of $3.64. This new low was reached on below average trading volume as 241,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Over the past year, Assembly Biosciences Inc. ...
Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with rec...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...